Peritoneal Cancer
📧 Sign up to get email alerts when something new happens for Peritoneal Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery [EARLY_Phase 1]
An early-phase clinical trial is evaluating olaparib for newly diagnosed BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancers …
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer
A clinical trial update from Shanghai Gynecologic Oncology Group describes an active-but-not-recruiting study evaluating an AI-assisted mode…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 3]
A Phase 3 clinical trial is evaluating mirvetuximab soravtansine plus bevacizumab versus bevacizumab alone as maintenance therapy in platinu…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
This document provides a status update on a Phase 2 clinical trial evaluating adavosertib with or without olaparib for recurrent ovarian, fa…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Genomic BRCA and Extensive ovArian Cancer Testing
A completed clinical trial evaluated BRCA genomic testing and extensive ovarian cancer testing in epithelial ovarian cancer, primary periton…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
This clinical trial update reports that data collection is ongoing for patients with low-grade ovarian and peritoneal tumors, with recruitme…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy [Phase 2]
This Phase II randomized, open-label trial evaluates whether NiraParib maintenance after 3 cycles of platinum-based chemotherapy is non-infe…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy
AbbVie-sponsored clinical study in Italy to evaluate folate receptor alpha expression in adults with ovarian, fallopian tube, or primary per…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
This Phase 2 trial is evaluating the combination of lenvatinib, pembrolizumab, and paclitaxel for recurrent endometrial, ovarian, fallopian …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer [EARLY_Phase 1]
This is a Phase 1 trial evaluating hyperthermic intraperitoneal chemotherapy with cisplatin during or before surgery for Stage III/IV ovaria…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial evaluating PLX038 for metastatic platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal can…
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery [Phase 2]
Bevacizumab is being studied in a Phase 2 trial for ovarian cancer patients undergoing second-look surgery. The trial is currently active bu…
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers [Phase 1]
Phase 1 trial to evaluate the safety and preliminary effectiveness of 27T51, a MUC16-targeting immune cell therapy, in adults with recurrent…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
A prospective cohort trial is recruiting germline BRCA1/BRCA2 variant carriers to study cancer risk in ovarian, fallopian tube, and primary …
-
CLINICAL_TRIALS other · 2026-01-29Clinical Trial Update: Diet, Hepcidin, and Chemotherapy RDI
George Washington University announces an active-not-recruiting clinical trial evaluating how diet and hepcidin affect chemotherapy dose int…
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-23EMA Authorised: Elahere (mirvetuximab soravtansine) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Elahere (mirvetuximab soravtansine) for ovarian cancer, fallopian tube cancer and peritoneal cancer…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating Raludotatug Deruxtecan (R-DXd) in platinum-resistant, high-grade ovarian cancer, primary peritoneal ca…